BACKGROUND Both bone marrow-derived mesenchymal stem cells (MSCs) and c-kit þ cardiac stem cells (CSCs)
T here is accumulating evidence that mesenchymal stem cells (MSCs) are a safe and efficacious approach to treating disorders characterized by left ventricular (LV) remodeling (1) (2) (3) . MSCs are antifibrotic (4, 5) , produce LV reverse remodeling (6) in both preclinical models and in patients (7) , and improve the quality of life in patients with heart failure secondary to ischemic cardiomyopathy (1, 2, (8) (9) (10) . It remains important, however, to define strategies that enhance the actions of MSCs. We previously showed that transepicardial injection of human MSCs plus c-kit þ cardiac stem cells (CSCs) into immunosuppressed swine 2 weeks post-myocardial infarction (MI) improved LV performance and reduced myocardial scarring to a greater degree than either cell type alone (11) .
Similarly, we showed that cell engraftment and systolic and diastolic recovery were superior with combination therapy. The goal of the present study was to determine whether transendocardial administration of autologous MSCs plus CSCs would similarly produce greater therapeutic potential than MSCs alone in a swine model of chronic heart failure due to post-infarct LV remodeling.
METHODS
All experiments were conducted in female Göttingen swine (12) . Twenty-eight animals survived a closedchest ischemic reperfusion MI induced by inflation of a coronary angioplasty balloon in the mid-left anterior descending artery, as previously described (12) formed (12) (13) (14) . The study design is outlined in Online Figure 1 , and the timeline for serial measurements of cardiac function are shown in Online Table 1 .
CELL MANUFACTURING AND DELIVERY. CSCs were isolated from 5 to 8 endomyocardial biopsy specimens
(1 to 2 mm) obtained from the septal wall of the right ventricle immediately after MI/reperfusion; they were then expanded, harvested, and cryopreserved as previously described (15) (16) (17) . MSCs were isolated from bone marrow obtained from the tibial cavity, as reported elsewhere (11) . On the morning of stem cell injection, the cells were thawed, washed, re-suspended in Plasma-Lyte A (Abbott Laboratories, North Chicago, 
RESULTS
Baseline and post-MI conditions for all animals were assessed (Online Table 2 ). There were no differences between groups for body weight or age at baseline or at scheduled time points (Online Tables 1 and 2 Tables 3 and 4 ).
All study groups had similar infarct sizes, whether evaluated as a percentage of LV mass or absolute scar size 3 months after infarction (Online Table 5 ). 
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